1. Annual report 2024
  2. Research
  3. RWEpi

RWEpi

Real World Epidemiology Research Group

RWEpi is a multidisciplinary team that includes epidemiologists, statisticians, health professionals, data scientists and pre- and post-doctoral researchers with extensive experience in the analysis and interpretation of real-world data. The main objective is to generate reliable scientific evidence through the use of data collected routinely in different environments of the health system.

The group participates in national and international studies focused on understanding the natural history and determinants of multiple diseases, the safety and efficacy of new drugs and vaccines, and the implementation of methods to analyze and evaluate the quality of real-world data. It also carries out research in the paediatric population and pregnant women, with the creation of a large cohort linking the electronic medical record of primary care in Catalonia of mothers and children; as well as health inequalities and the role of lifestyle and environmental exposures in health.

Group projects

  • DARWIN-EU. European Medicines Agency (EMA). 2022IP: Talita Duarte Salles.
  • Plataforma IMPACT - Programa 2 - Ciencia de Datos. (IMP/00019). Barcelona Supercomputing Center (BSC-CNS); Instituto de Salud Carlos III. 2020-2024. IP: María Aragón Pérez.
  • COMPARTIM, App per persones amb DI lleugera o moderada. IP: Diana Puente Baliarda.
  • Iniciación práctica al análisis de datos OMOP. IP: Talita Duarte Salles.
  • DARWIN EU® - Incidence of suicidality in patients with specific chronic skin conditions. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2027. IP: Talita Duarte Salles.
  • DARWIN EU® - Suicidality following exposure to doxycycline. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Comparing direct and indirect methods to estimate prevalence of chronic diseases using real-world data. ERASMUS   UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2025. IP: Talita Duarte Salles.
  • Temporal trends of mental disorders from 2006 to 2024 using large real-world data. 2024-2025. IP: Andrea Pistillo .
  • Time trends in prevalence, incideTime trends in prevalence, incidence and survival of cancer in the OHDSI Networknce and survival of cancer.   2024-2026. IP: Talita Duarte Salles.
  • DARWIN EU® - Effectiveness of COVID-19 vaccines on severe COVID-19 and post-acute outcomes of SARS-CoV-2 infection. ERASMUS   UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2026. IP: Talita Duarte Salles.
  • DARWIN EU® - Age-specific incidence rates of RSV-related disease in Europe. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM   (EMC). 2024-2025. IP: Talita Duarte Salles.
  • Adiposidad durante la vida y riesgo y mortalidad de cáncer: el rol de comorbilidades e intervenciones para pérdida de peso. (PI23/01186).   Instituto de Salud Carlos III. 2024-2026. IP: Talita Duarte Salles.
  • DARWIN EU® - Monitoring prescription of medicines for public health emergencies at risk of shortages. ERASMUS UNIVERSITAIR MEDISCH   CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the   context of the OMICRON variant. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - DUS in patients with major depressive disorder. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus. ERASMUS   UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - DUS of medicines with prokinetic properties in children and adults diagnosed with gastroparesis. ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.
  • DARWIN EU® - Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations. ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.
  • DARWIN EU® - Use of take-home naloxone for opioid overdose treatment. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC).   2023-2024. IP: Talita Duarte Salles.
  • DARWIN EU® - Drug utilization study of prescription opioids. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024.   IP: Talita Duarte Salles.
  • Development of new growth curves for children and adolescents in Catalonia. 2023-2026. IP: Talita Duarte Salles.
  • DARWIN EU® - Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022. 2023-2024. IP: Talita Duarte   Salles.
  • Short term effects of temperature and air pollution on health in Barcelona and its metropolitan area considering sociodemographic and   geographical inequalities. 2023-2026. IP: Andrea Pistillo.
  • Real-world coverage and effectiveness of COVID-19 vaccines in vulnerable populations living in Catalonia. Institut d'Investigació en Atenció   Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Talita Duarte Salles.
  • Maternal Urban Exposures, Socioeconomic Context, and Birth Outcomes: A Population Based Longitudinal Study in Catalonia, Spain. 2023-2026. IP: Alicia Abellan Ecija.
  • DARWIN EU® - Background rates of serious adverse events to contextualise safety signals in a clinical trial in adolescent and adult patients   with severe asthma. 2023-2024. IP: Talita Duarte Salles.
  • Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023-2026. IP: Carlen Reyes   Reyes.
  • DARWIN EU® - D2.2.5_C1-001_V1.0_IDIAP rare blood cancer. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC).   2022-2024. IP: Talita Duarte Salles.
  • DARWIN EU® - DUS of Antibiotics in the 'Watch' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use.   2022-2024. IP: Talita Duarte Salles.
  • Effects of temperature and air pollution on mental health in Barcelona and its metropolitan area considering sociodemographic and  geographical inequalities. (74036228-32). Institut Municipal Hisenda BCN - AJUNTAMENT DE BARCELONA. 2022-2024. IP: Talita Duarte Salles.
  • DARWIN EU® - Drug utilisation of valproate-containing medicinal products in women of childbearing potential. ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC). 2022-2024. IP: Talita Duarte Salles.
  • Proyecto validación Lantitaps. 2022-2025. IP: Diana Puente Baliarda.
  • Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely   collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022-2025. IP:Carlen Reyes Reyes.
  • Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció   Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Carlen Reyes Reyes.
  • Characterisation and risks of long-term COVID-19 outcomes using large real world data. Instituto de Salud Carlos III. 2022-2025. IP: Talita   Duarte Salles.
  • Time trends and socioeconomic factors associated with cancer incidence for five solid tumour sites in Catalonia from 2009 to 2018. Institut   d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Talita Duarte Salles.
  • Air pollution in relation to COVID-19 morbidity and mortality: a large population-based cohort study in Catalonia, Spain (COVAIR-CAT).   Fundación Privada Instituto de Salud Global Barcelona (ISGlobal). 2022-2025. IP: Talita Duarte Salles.
  • Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus. University of California, Los  Angeles campus (UCLA). 2022-2025. IP: Talita Duarte Salles.
  • Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine. IQVIA Solutions BV.2022-2025. IP: Talita Duarte Salles.
  • Urban and social environment and childhood obesity - a natural moving2health experiment. Fundacio "la Caixa". 2021-2024. IP: Talita Duarte Salles.
  • Research Protocol for an Observational Health Data Analysis to Assess the Long-term Outcomes of Prostate Cancer Patients Undergoing Non-Interventional Management (i.e., Watchful Waiting) and the Impact of Comorbidities and Life Expectancy- PIONEER IMI's "Big Data for Better Outcomes" program. STICHTING EUROPEAN UROLOGICAL FOUNDATION. 2021-2024. IP: Talita Duarte Salles.
  • Drug utilisation studies using data mapped to the OMOP Common Data Model: a proof of concept study assessing respiratory drug use in  patients with asthma or COPD. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2021-2024. IP: Talita Duarte Salles.
  • Real world trends in surgical procedures- an international network study. University of Oxford. 2021-2024. IP: Talita Duarte Salles.
  • UNravelling COVID-19 through rEal-woRld data (UNCOVER). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021IP:Talita Duarte Salles.
  • Examining the etiology of early-onset colorectal cancer (EOCRC) in the SIDIAP database - research protocol. International Agency for    Research on Cancer (IARC). 2021-2024. IP: Talita Duarte Salles.
  • Systemic glucocorticoids in the treatment of COVID-19 and risks of adverse outcomes in COVID-19 patients in the primary and secondary care setting. IQVIA Solutions BV. 2021-2024. IP: Talita Duarte Salles.
  • Impact of EU label changes fluoroquinolone containing medicinal products for systemic and inhalation use: post-referral prescribing trends.   IQVIA Solutions BV. 2021-2024. IP: Talita Duarte Salles.
  • The descriptive epidemiology of Adverse Events of Special Interest for COVID-19 and other vaccines and after seasonal influenza and COVID-19 disease in SIDIAP. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. IP: Talita Duarte Salles.
  • Risk of mental and behavioral disorders in relation to availability of green spaces. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. IP: Talita Duarte Salles.
  • Associations between playspaces and childhood overweight and obesity in Barcelona. Institut d'Investigació en Atenció Primària Jordi Gol i   Gurina (IDIAPJGol). 2021-2024. IP: Talita Duarte Salles.
  • Drug Utilization Study (DUS) and Post Authorization Safety Study (PASS) on the fixed combination tramadol-dexketoprofen (DKP-TRAM). SIMG
  • Società Italiana di Medicina Generale e delle cure primarie; SIMG SERVICE CONGRESS AND EDUCATION S.R.L. 2021-2024. IP: Talita Duarte Salles.
  • Cohorte DESVELA. Análisis del papel de las aptitudes personales como DEterminantes de la incidencia de morbilidad, eStilos de vida, calidad   de Vida, uso de sErvicios y mortaLidAd. (PI19/01285). Instituto de Salud Carlos III. 2019-2024. IP: Diana Puente Baliarda,Bonaventura Bolíbar Ribas.
  • European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes.
  • DARWIN EU® - Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products. ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics.   ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2027. IP: Talita Duarte Salles.
  • Incidencia y asociación entre la exposición a las medicaciones potencialmente inapropiadas de la herramienta STOPPFall y el riesgo de eventos   adversos: estudio de cohortes de base poblacional. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP:   Carlen Reyes Reyes.
  • DARWIN EU® - Characterising STOPP criteria medication use in people with recurrent falls. ERASMUS UNIVERSITAIR MEDISCH CENTRUM   ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Antipsychotic prescribing in Europe: a descriptive analysis of trends and patient characteristics. European Medicines Agency   (EMA). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe. ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Azathioprine - user characteristics. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines   Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications (P3 C1-004). ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • DARWIN EU® - Drug Utilisation Studies on GLP-1 Agonists. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European   Medicines Agency (EMA). 2024-2024. IP: Talita Duarte Salles.
  • Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe.   Abbvie INC. 2024-2027. IP: Talita Duarte Salles.
  • DARWIN EU® - Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer. ERASMUS UNIVERSITAIR MEDISCH   CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • Asociación entre los niveles de vitamina D en sangre, los suplementos con vitamina D y las fracturas osteoporóticas en la población catalana:   estudio de base poblacional. 2024-2027. IP: Carlen Reyes Reyes.
  • Incidence, prevalence, and characterisation of medicines with suggested drug shortages in Europe. 2024-2026. IP: Talita Duarte Salles.
  • Characterization of incidental and chronic use of macrolides in patients with asthma, chronic obstructive pulmonary disease (COPD), and   asthma-COPD overlap syndrome (ACOS); a pharmacoepidemiologic drug utilization study with data mapped to the Observational Medical   Outcomes Partnership - Common Data Model (OMOP-CDM). ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2027. IP: Talita Duarte Salles.
  • DARWIN EU® - Frailty and polypharmacy among adults aged 18 and above with cancer at the time of diagnosis. ERASMUS UNIVERSITAIR   MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
  • Incidence and prevalence of psoriasis and psoriatic arthritis and the external validation of a prediction model for the development of psoriatic   arthritis at 10 years in people diagnosed with psoriasis: a cohort study. Barcelona Supercomputing Center (BSC-CNS). 2023-2026. IP: IP no   primaria-,Talita Duarte Salles.

Group publications

  • Sahr JN, Bennett M, Medina Perucha L, Jacques Aviño C. Emotional health in adolescents from a critical perspective: Photo-elicitation in a cross-cultural neighborhood. SSM-Qual. Res. Health. 2025;7
  • Nguyen Thi Khanh H, Rigau Sabadell M, Khomenko S, Pereira Barboza E, Cirach M, Duarte Salles T et al. Ambient air pollution, urban green space and childhood overweight and obesity: A health impact assessment for Barcelona, Spain. Environ Res. 2025;264(Pt 1):120306-120306. PMID:39510226.
  • Lozano Sánchez A, Aragonès E, López Jiménez T, Bennett M, Evangelidou S, Francisco E et al. Temporal trends and social inequities in adolescent and young adult mental health disorders in Catalonia, Spain: a 2008-2022 primary care cohort study. Child Adolesc. Psychiatry Ment. Health. 2024;18(1):159-159. PMID:39695666.
  • Pistillo A, Warkentin S, Abellana A, de Bonte J, Ranger T, Pérez Crespo L et al. Residential relocation and changes in patterns of environmental exposures by health determinants among children and adolescents in Catalonia, Spain. Environ Res. 2024;263(Pt 2):120152-120152. PMID:39419256.
  • Du M, Dernie F, Català M, Delmestri A, Man WY, Brash JT et al. Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries. Eur J Intern Med. 2024;130106-117. PMID:39134452.
  • López Sánchez I, Perramon Malavez A, Soriano Arandes A, Prats C, Duarte Salles T, Raventós B et al. Socioeconomic inequalities in COVID-19 infection and vaccine uptake among children and adolescents in Catalonia, Spain: a population-based cohort study. Front Pediatr. 2024;121466884-1466884. PMID:39633820.
  • Xie JQ, López Güell K, Dedman D, Duarte Salles T, Kolde R, López Blasco R et al. Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data. EClinicalMedicine. 2024;77102903-102903. PMID:39552716.
  • Dernie F, Corby G, Robinson A, Bezer J, Mercade Besora N, Griffier R et al. Standardised and Reproducible Phenotyping Using Distributed Analytics and Tools in the Data Analysis and Real World Interrogation Network (DARWIN EU). Pharmacoepidemiol Drug Saf. 2024;33(11):PMID:39532529.
  • Guo Y, Raventós B, Català M, Elhussein L, López Güell K, Tan EH et al. Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones. Pharmacoepidemiol Drug Saf. 2024;33(10):PMID:39414581.
  • Corby G, Barclay NL, Tan EH, Burn E, Delmestri A, Duarte Salles T et al. Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study. Transl Lung Cancer Res. 2024;13(9):2187-2201. PMID:39430337.
  • Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A et al. Incidence, Prevalence, and Survival of Prostate Cancer in the UK. JAMA Netw Open. 2024;7(9):PMID:39298169.
  • Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F et al. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM. J. Am. Coll. Cardiol. 2024;84(10):904-917. PMID:39197980.
  • Tonne C, Ranzani O, Alari A, Ballester J, Basagaña X, Chaccour C et al. Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia, Spain (COVAIR-CAT). Res Rep Health Eff Inst. 2024;2024(220):1-48. PMID:39468856.
  • Barclay NL, Burn E, Delmestri A, Duarte Salles T, Golozar A, Man WY et al. Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021. Sci Rep. 2024;14(1):19069-19069. PMID:39153995.
  • López Jiménez T, Plana Ripoll O, Duarte Salles T, Recalde M, Bennett M, Xavier Cos F et al. Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia. Cancer Med. 2024;13(16):PMID:39149842.
  • Koch S, Peralta GP, Carsin AE, Abellan A, Roda C, Torrent M et al. Physical activity and body mass related to catch-up lung function growth in childhood: a population-based accelerated cohort study. Thorax. 2024;79(8):762-769. PMID:38448222.
  • Lazar Neto F, Mercadé Besora N, Raventós B, Pérez Crespo L, Castro Junior G, Ranzani OT et al. Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain. Nat Commun. 2024;15(1):5088-5088. PMID:38898035.
  • Mercadé Besora N, Li X, Kolde R, Trinh NT, Sanchez Santos MT, Man WY et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart. 2024;110(9):635-643. PMID:38471729.
  • Reyes C, Newby D, Raventós B, Verhamme K, Mosseveld M, Prieto Alhambra D et al. Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study. Age Ageing. 2024;53(5):PMID:38783756.
  • Barclay NL, Moncusi MP, Jödicke AM, Prieto Alhambra D, Raventós B, Newby D et al. The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study. Front Oncol. 2024;141370862-1370862. PMID:38601756.
  • Català M, Mercadé Besora N, Kolde R, Trinh NTH, Roel E, Burn E et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;12(3):225-236. PMID:38219763.
  • Abellan A, Warembourg C, Mensink Bout SM, Ambros A, de Castro M, Fossati S et al. Urban environment during pregnancy and lung function, wheezing, and asthma in school-age children. The generation R study. Environ Pollut. 2024;344123345-123345. PMID:38219897.
  • Ranzani O, Alari A, Olmos S, Milà C, Rico A, Basagaña X et al. Who is more vulnerable to effects of long-term exposure to air pollution on COVID-19 hospitalisation?. Environ Int. 2024;185108530-108530. PMID:38422877.
  • Alari A, Ranzani O, Olmos S, Milà C, Rico A, Ballester J et al. Short-term exposure to air pollution and hospital admission after COVID-19 in Catalonia: the COVAIR-CAT study. Int J Epidemiol. 2024;53(2):PMID:38514998.
  • Markus AF, Rijnbeek PR, Kors JA, Burn E, Duarte Salles T, Haug M et al. Real-world treatment trajectories of adults with newly diagnosed asthma or COPD. BMJ Open Respir Res. 2024;11(1):PMID:38413124.
  • Torrell G, Puente D, Jacques Aviñó C, Carrasco Ribelles LA, Violán C, Lopez Jiménez T et al. Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia. BMC Infect Dis. 2024;24(1):82-82. PMID:38225587.
  • Lo Re VI, Cocoros NM, Hubbard RA, Dutcher SK, Newcomb CW, Connolly JG et al. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States. Clin Epidemiol. 2024;1671-89. PMID:38357585.
  • Fabiano G, Chen XH, Rathod Mistry T, Delmestri A, Njuki LN, Moayyeri A et al. Feasibility of a Federated Network Analysis Using Real-World Data Mapped to OMOP Common Data Model to Estimate Healthcare Resource Utilisation and Costs of Imminent Subsequent Fracture. Pharmacoepidemiol Drug Saf. 2024;33391-391.
  • Verhamme KMC, Ridder M, Arinze JT, Inberg G, Delmestri A, Burn E et al. DARWIN EU®-Background Rates of Outcomes of Interest in Patients with Severe Asthma. Pharmacoepidemiol Drug Saf. 2024;33685-685.
  • Vojinovic D, Arinze JT, Delmestri A, Brash J, Seager S, Verdy G et al. DARWIN EU®-Drug Utilisation Study of Medicines with Prokinetic Properties in Children and Adults Diagnosed with Gastroparesis. Pharmacoepidemiol Drug Saf. 2024;3391-92.
  • Raventós B, Chen XH, Stanford T, Prieto Alhambra D, Porce LM, Reyes C et al. Prescription Sequence Symmetry Analysis to Identify Prescription Cascades for Dementia Drug Treatments in the United Kingdom. Pharmacoepidemiol Drug Saf. 2024;33399-400.
  • Chen XH, Raventós B, Stanford T, Prieto Alhambra D, Burn E, Català M et al. Using Prescription Symmetry Sequence Analysis in the Context of Antiparkinsonian Treatments in the United Kingdom. Pharmacoepidemiol Drug Saf. 2024;3327-27.
  • De Ridder M, Arinze J, Inberg G, Delmestri A, Burn E, Mayer MA et al. DARWIN EU®- Background rates of clinical outcomes of interest in patients with severe asthma. Eur. Resp. J. 2024;64
  • Arinze JT, Mayer M, Verdy G, Van Kessel M, Ramírez Anguita JM, Leis A et al. RSV-associated clinical outcomes: A decade of insight from 52 million people across Europe. Eur. Resp. J. 2024;6
  • Chen X, Rathod Mistry T, Fabiano G, Moayyeri A, Warden J, Reyes C et al. Subsequent fractures in postmenopausal women with fragility fractures: incidence and patient characteristics from six European countries. Aging Clin. Exp. Res. 2024;36605-605.
Anar a l'inici